A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 12‐week efficacy, safety and speed of response from a randomized, double‐blinded trial

BACKGROUND: Patients with psoriasis value rapid and complete skin clearance. No head‐to‐head studies have focused on early responses to interleukin (IL)‐17 vs. IL‐23 inhibitors. OBJECTIVES: To compare early and complete skin clearance by the IL‐17A inhibitor ixekizumab vs. the IL‐23p19 inhibitor gus...

Descripción completa

Detalles Bibliográficos
Autores principales: Blauvelt, A., Papp, K., Gottlieb, A., Jarell, A., Reich, K., Maari, C., Gordon, K.B., Ferris, L.K., Langley, R.G., Tada, Y., Lima, R.G., Elmaraghy, H., Gallo, G., Renda, L., Park, S.Y., Burge, R., Bagel, J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7317420/
https://www.ncbi.nlm.nih.gov/pubmed/31887225
http://dx.doi.org/10.1111/bjd.18851

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7317420/
https://www.ncbi.nlm.nih.gov/pubmed/31887225
http://dx.doi.org/10.1111/bjd.18851

Ejemplares similares